Hypera SA
BOVESPA:HYPE3
Gross Margin
Hypera SA
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| BR |
|
Hypera SA
BOVESPA:HYPE3
|
14.6B BRL |
59%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
696.2B USD |
82%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
371B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204.9B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
178.1B CHF |
76%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
158.8B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
192B USD |
79%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.5B EUR |
70%
|
Hypera SA
Glance View
Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Hypera SA's most recent financial statements, the company has Gross Margin of 58.9%.
You don't have any saved screeners yet